Clinical Trial Update: Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia [Phase 3]

View source ↗

Summary

A Phase 3 double-blind, placebo-controlled trial evaluating ondansetron in schizophrenia and related disorders has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia
• Schizophreniform Disorder

Drugs mentioned

• Ondansetron (ondansetron)

Snippet

Sponsor: Bayside Health | Conditions: Schizoaffective and Schizophreniform Disorders, Schizophrenia | Phase 3 | Status: COMPLETED